Navigation Links
Novartis marks World CML Day with update on global research program to evaluate whether Ph+ CML patients can live treatment-free
Date:9/19/2013

tinues," "commitment," "providing support," or similar expressions, or by express or implied discussions regarding potential new indications or labeling for Novartis Ph+ CML products or regarding potential future revenues from such products. You should not place undue reliance on these statements.  Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with a Novartis Ph+ CML product to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that any Novartis Ph+ CML product will be approved for any additional indications or labeling in any market. Nor can there be any guarantee that any Novartis Ph+ CML product will achieve any particular levels of revenue in the future. In particular, management's expectations regarding such products could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; unexpected manufacturing issues; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the infor
'/>"/>
SOURCE Novartis
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Global Lung Cancer Therapeutics Market 2013 Report Featuring Leading Players Such As AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Co., GlaxoSmithKline, Hoffmann-La Roche, Novartis And Others
2. Novartis highlights new findings in advancing care for patients with 170 abstracts in breast, lung and blood cancers at ASCO and EHA
3. Leaders from Pfizer, Novartis and J&J Challenge Industry to Disrupt R&D
4. Novartis launches the Cancer Cell Line Encyclopedia to catalog worlds cancer cell lines
5. Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims
6. Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts
7. Spanish researchers writing in cell describe the 9 hallmarks of aging
8. Discovery of gene mutation causing Sturge-Weber syndrome, port-wine stain birthmarks offers new hope
9. Nutra Pharma Patent and Trademarks Published in India
10. Spider Bully for Less: My Cleaning Products Marks Down the Spray for its Christmas Special
11. My Cleaning Products Marks Down Its Bed Bug Bully Price by 20%
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... May 20, 2015 Research and Markets ... of the "2015 Global Survey on Flow ... The primary goal of this research ... instruments and reagents. Key information the survey seeks ... of flow cytometers, predominantly used applications for flow ...
(Date:5/20/2015)... , May 20, 2015 Research and Markets ... the "Top Technologies in HW_Technical Insights" report ... this report evaluated technology trends in the Health and ... are likely to have an impact in the year ... of the top 10 health and wellness technologies that ...
(Date:5/20/2015)... DENVER , May 20, 2015  Health ... connecting short-staffed healthcare organizations with job seekers looking ... SHIFT , a new mobile and online tool ... the healthcare industry. SHIFT enables employers ... locum tenens, travel nursing, per diem and other ...
(Date:5/20/2015)... 20, 2015  Resolution Bioscience announced today the successful ... TM , a blood-based liquid biopsy for an ALK-gene ... (NSCLC), the most common form of this cancer. Researchers ... patients to personalized therapies and direct them into clinical ... Department of Health, the CLIA authority in ...
Breaking Biology Technology:Global Survey on Flow Cytometry Adoption Trends 2015 2Top Technologies in the Health and Wellness Industry 2015 2Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 2Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 3Resolution Bioscience Receives CLIA Certification for its Diagnostic Laboratory and Launches CLIA-Certified Liquid Biopsy for Lung Cancer 2
... 31 Thermage, Inc.,(Nasdaq: THRM ), announced today ... quarter ended June 30, 2008, after the market close ... a conference call and,webcast on Tuesday, August 12, 2008, ... the financial results and current corporate,developments. The dial-in number ...
... Ranexa Revenue Grows 15 Percent Quarter-over-Quarter -, PALO ALTO, ... today reported financial results for the second quarter,ended June 30, ... Company reported a net loss of,$4.3 million, or $0.07 per ... $0.53 per share, for the prior quarter ended March 31, ...
... President of MicroMass,Communications, Inc., a leader in behavioral ... as one of the 100 most,inspiring and influential ... honor was announced in the July/August issue of ... all areas of the pharmaceutical,industry. Candidates were nominated ...
Cached Biology Technology:CV Therapeutics Reports 2008 Second Quarter Financial Results 2CV Therapeutics Reports 2008 Second Quarter Financial Results 3CV Therapeutics Reports 2008 Second Quarter Financial Results 4CV Therapeutics Reports 2008 Second Quarter Financial Results 5CV Therapeutics Reports 2008 Second Quarter Financial Results 6CV Therapeutics Reports 2008 Second Quarter Financial Results 7MicroMass President Jay Bigelow Named to PharmaVOICE List of 100 Most Inspiring and Influential Leaders in the Life Sciences 2MicroMass President Jay Bigelow Named to PharmaVOICE List of 100 Most Inspiring and Influential Leaders in the Life Sciences 3
(Date:5/21/2015)... May 21, 2015 The Sync Project™ ... music for health, today announced a collaborative partnership with ... partnership will center on collaboration on original research, joint ... step in the collaboration, The Sync Project and BerkleeICE ... as Medicine" in the 2015-2016 academic year.  ...
(Date:5/19/2015)... -- Technology is rapidly advancing, outpacing enterprises, ability to secure ... and their management are soon to be rendered obsolete ... as those developed by the FIDO Alliance™. With the ... BYOD, COPE, IoT, and mobile payments, the interconnected online ... In response to the call for seamless, secure, ...
(Date:5/14/2015)... , May 14, 2015  Verificient Technologies, ... verification and online remote proctoring, announced a ... (SaaS) company and creator of the Canvas ... the two companies will benefit from the ... As a fully integrated multifactor ...
Breaking Biology News(10 mins):The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2
... Tibetan sacred mountain Khawa Karpo, a verdant, snow-capped high ... world,s most exceptional areas of plant and animal diversity ... endangered snow leopard. Monsoon rains, precipitous topography dissected by ... have influenced this region, valued not only for its ...
... 12, 2012 Wake Forest Baptist Medical Center ... academic and clinical research and discoveries into marketable products ... Wake Forest Innovations, is being led by Chief Innovation ... is also President of the Piedmont Triad Research ...
... in Northern California and Oregon may be linked to a ... by scientists from the University of California, Davis. Their findings, ... could lead to a better understanding of how viruses can ... March 2010 by scientists at the UC Davis School of ...
Cached Biology News:New book details the biological and cultural diversity of Khawa Karpo, sacred mountain of Tibet 2New book details the biological and cultural diversity of Khawa Karpo, sacred mountain of Tibet 3Wake Forest Baptist Medical Center Launches Wake Forest Innovations 2Wake Forest Baptist Medical Center Launches Wake Forest Innovations 3Emerging virus in raccoons may provide cancer clues 2Emerging virus in raccoons may provide cancer clues 3
... Radiochemical Purity is >95%NEN Radiolabeled Ligands\n\nReceptor-related research ... availability of new radiolabeled ligands selected to ... a wide range of products and services ... over 400 state-of-the-art radioligands. If you do ...
... enables sensitive and specific detection of microRNAs ... probes have high binding affinity and discrimination, ... miRNAs. Due to the high binding affinity ... 1/10 the amount of sample is needed ...
Rabbit polyclonal to Vitronectin ( Abpromise for all tested applications). Antigen: Full length Vitronectin protein (Mouse). Entrez Gene ID: 7448 Swiss Protein ID: P04004...
... monoclonal [PRMT5-21] to PRMT5 Arginine methylation ... has only recently been linked to protein ... enzymes have been identified in mammalian cells. ... essential regulatory functions by methylation of key ...
Biology Products: